Genmab — April 2024

[LP90]

Godmorgen det gode ved aktien er faldet så meget er at den jo så også kan stige meget

[w]

jo længere ned den kommer,
jo flere aktier kan ledelsen ta' ud af markedet

[w]

Jeg faldt over Roei Mazor's kommentar på linkedin i forbindelse med FDA's mrd beslutning og hvad det kunne medføre for hexCD38: "Fascinating to see this asset in action".

[w]

tester han stoffet på sin klinik?

[JKY_VH]

Pas, men et eller andet har han jo tydeligvis set.

[E_L]

Roche Q1 '24 Lunsumio CHF16mn Columvi CHF 25mn

[E_L]

AbbVie Epkinly US $12, Intern. $15, Total $27. Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain
international territories

[E_L]

https://investors.abbvie.com/static-files/af510304-0bc1-4781-9090-b6c4a9be5edb

[E_L]

it's a bit difficult to get the exact total sales # out of this, i assume x2 for now. (Last year full 2023 Abbvie reported full year $31mn versus Genmab $64)

[E_L]

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Rybrevant. PAPILLON -amivantamab in combination with carboplatin and
pemetrexed for the first-line treatment https://www.ema.europa.eu/en/medicines/human/variation/rybrevant

[E_L]

tisotumab vedotin submission in japan
https://genmab.co.jp/pressrelease/

[E_L]

AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY https://www.amgen.com/newsroom/press-releases/2024/04/amgen-to-submit-teprotumumab-marketing-authorization-application-to-the-european-medicines-agency

[E_L]

In March 2024, Amgen submitted a marketing authorization application to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain, a New Drug Submission (NDS) to Health Canada and an application to the Therapeutic Goods Administration (TGA) in Australia for teprotumumab. Teprotumumab is also under review by the Ministry of Health, Labour and Welfare (MHLW) in Japan.

[Helge_LarsenPI-redaktør]

Godmorgen

[transalp]

Go morgen..

[bibob]

God morgen.

[LP90]

Godmorgen

[Stroka]

God morgen

[ProinvestorNEWS]

Genmab-partner vil have Tepezza godkendt i EU
i dag kl. 08:04 ∙ MarketWire

Genmabs amerikanske partner Amgen vil have øjenmidlet Tepezza godkendt til markedsføring i EU.

Det skriver Amgen i en pressemeddelelse ifølge Medwatch.

I pressemeddelelsen oplyses det, at Amgen har indsendt en markedsføringsansøgning for Tepezza til de europæiske myndigheder.

[ProinvestorNEWS]

Tepezza er udviklet af Genmab til øjensygdommen Thyroid Eye Disease (TED) og har siden starten af 2020 været godkendt i USA.

Salget har i USA hidtil været varetaget af selskabet Horizon Therapeutics, der i oktober 2023 blev opkøbt af Amgen.

Hvis Tepezza, der er baseret på virkemidlet Teprotumumab, godkendes, vil det ifølge Medwatch være det eneste lægemiddel, der er godkendt til behandling af TED i EU. Midlet markedsføres desuden i Brasilien og Saudi-Arabien.